Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer.
OBJECTIVE
To evaluate the potential of heat-killed Mycobacterium vaccae (SRL172) as a nonspecific immunostimulant and as an adjuvant to whole tumour cell vaccination in the rat model of prostate cancer.


METHODS
SRL172 was used as a vaccine in the prevention and treatment of subcutaneous tumours in rats. Prevention experiments were conducted using subcutaneous MAT-LyLu tumours in Copenhagen rats, comparing vaccination with SRL172 alone, SRL172 plus autologous cells, and bacille Calmette-Guèrin (BCG) plus autologous cells before tumour implantation. Treatment experiments were conducted using subcutaneous MAT-LyLu tumours in the Copenhagen rat and subcutaneous PAIII tumours in the Lobund-Wistar rat. Tumours were induced by subcutaneous injection with tumour cells. Animals were then vaccinated with autologous cells, autologous cells plus SRL172, or SRL172 alone.


RESULTS
SRL172 was effective as an adjuvant to autologous whole tumour cell vaccination in the prevention of MAT-LyLu tumours and the survival benefit was equivalent to that provided when the adjuvant was live-attenuated BCG. SRL172 alone did not reduce tumour take or tumour growth in this model and neither strategy was effective in delaying the growth of established MAT-LyLu tumours. In the Lobund-Wistar rat vaccination with autologous whole tumour cells and SRL172 significantly delayed the growth of established tumours.


CONCLUSIONS
Mycobacterium vaccae deserves further evaluation as an adjuvant to whole tumour cell vaccination in a phase I clinical trial in patients with prostate cancer.
Hrouda
D
D
Department of Urology, St George's Hospital, London, UK.
Souberbielle
B E
BE
Kayaga
J
J
Corbishley
C M
CM
Kirby
R S
RS
Dalgleish
A G
AG
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D008297:Male; D009161:Mycobacterium / Q000276:immunology*; D009368:Neoplasm Transplantation; D011471:Prostatic Neoplasms / Q000628:therapy*; D051381:Rats; D017208:Rats, Wistar; D016019:Survival Analysis; D015164:Vaccines, Inactivated / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D001428:Bacterial Vaccines; D015164:Vaccines, Inactivated